ESTRO 2022

Session Item

Head and neck

Session Type: Poster (digital)

Track: Clinical

Journey:

Obesity potential biomarker for prediction of OS in head and treated with radio-chemotherapy

Giovanni Gadducci, Italy

Presentation Number: PO-1078

Abstract

Abstract Title:

Obesity potential biomarker for prediction of OS in head and treated with radio-chemotherapy

Authors:

Giovanni Gadducci¹, noemi giannini², giulia malfatti³, natalina coccia², taiusha fuentes², alessandra gonnelli², elisa calistri², fabiola paiar²

¹azienda ospedaliera universitaria pisana , radiotherapy, PISA, Italy; ²azienda ospedaliera universitaria pisana, radiotherapy, PISA, Italy; ³azienda ospedaliera universitaria pisana,, radiotherapy, PISA, Italy

Show Affiliations

Purpose or Objective

The prognosis of head and neck cancer patients is traditionally determined using several different clinical characteristics such age, stage, high alcohol consumption and cigarette smoking.

The purpose of this study was to evaluate the prognostic relevance obesity (BMI> 29.9 Kg/m2) head and neck cancer (HNC) patients treated with radio-chemotherapy (RT/CT) at the Department of Radiotherapy, University of Pisa.

Material and Methods

BMI was retrospectively assessed in 134 HNC locally advanced patients (median age 63,5,range 20-84,M:F 4:1) treated between January 2015 to June 2020.

The following were the inclusion criteria:

All patients (> 18 years old) with locally advanced squamous cell carcinoma underwent adjuvant or exclusive radiotherapy concomitant with cisplatin, BMI was calculated before the beginning of RT/CT.

For the present study, overall survival (OS) and progression free survival (PFS) were defined as days between the end of the treatment and death or progression date of last follow-up.

Results

Patients with a BMI above 29.9 Kg/m 2 showed a favorable trend regarding the overall survival (p= 0,086; HR 0.489, IC 0.211-1,082) in univariate analysis.

Instead BMI was not corralated with PFS (p= 0,644; HR 0.802, IC 0.211-1,082).

Conclusion

In our study we have shown that obesity is a potential biomarker for patients with locally advanced HNC treated wih radiotherapy concomitant with cisplatin.

The role of obesity and BMI remain controverse in literature. These findings can be explained with a better nutritional status before the beginning of the therapy compared with normal and underweight population.

More prospective studies with larger population are required